Sponsor
Frank Pallone
Representative · D-NJ
Representative · D-NJ
Official title: To provide for lower costs for everyday Americans, and for other purposes.
Introduced March 3, 2025 by Frank Pallone · Last progress March 3, 2025
The bill seeks to lower drug costs and expand access (telehealth, home infusion, Medicaid/HCBS, public‑health preparedness) through greater transparency, funding, and regulation, but it does so by creating sizable new reporting, compliance, and spending obligations that may raise costs for taxpayers, provoke privacy and litigation risks, and disproportionately burden smaller providers and vendors.
Millions of patients, plan sponsors, and employers gain much greater price and rebate transparency as PBMs and plans must deliver standardized, machine‑readable, drug‑ and claims‑level reports and remit many rebates to plans, helping plans detect conflicts of interest and potentially lower premiums and out‑of‑pocket costs.
Expanded telehealth and home‑based care options (extended telehealth flexibilities, AHCaH extension, HSA telehealth safe‑harbor extension, Part B coverage for certain home infusion pumps/drugs) improve access and convenience for Medicare, Medicaid, and privately insured patients.
Stronger public‑health preparedness and medical countermeasure investments (regional biocontainment labs, diagnostics preparedness, surge capacity, cybersecurity for health systems) boost readiness and protect communities from future health emergencies.
States, providers, plans, PBMs, pharmacies, and other regulated entities face large new administrative and compliance burdens (frequent machine‑readable reporting, new audits, sampling, inventory/reporting mandates) that will consume staff time and systems resources.
The bill authorizes substantial new appropriations and multi‑year funding in many places (public‑health programs, countermeasures, Medicare/Medicaid changes, Part D/DME expansions), increasing federal outlays that could raise taxpayer costs or crowd out other priorities.
Compliance and reporting costs for PBMs, plans, manufacturers, pharmacies, and smaller vendors are likely to be passed through as higher premiums, administrative fees, or narrower plan options—disproportionately harming small employers, middle‑class families, and smaller PBMs/pharmacies.
Based on analysis of 37 sections of legislative text.
Imposes broad PBM and plan transparency/reporting, updates Medicare/Medicaid rules (provider enrollment, DSH, home infusion), strengthens consumer safety standards, funds preparedness and NTIA updates.
This bill is a broad package of health, consumer safety, technology, and public‑health measures aimed at lowering costs and increasing transparency. Key actions include new reporting and disclosure requirements for pharmacy benefit managers (PBMs) and group health plans; Medicaid and Medicare changes to ease provider enrollment and expand certain payment and program rules; consumer product safety bans and new mandatory safety standards for mobility batteries and devices; expanded telehealth coding and program evaluations; public health preparedness funding and strategy updates; and various FDA/NIH amendments to strengthen pediatric research and organ donation support. The bill creates multiple new disclosure and enforcement regimes (especially for PBMs and drug pricing), updates agency organization and funding (NTIA, CDC/PHE preparedness), mandates state Medicaid enrollment streamlining for out‑of‑State providers, revises Medicare hospital payment and home infusion rules, and directs GAO, MedPAC, and HHS studies and reports. Many provisions take effect on different schedules (some within months, many for plan years beginning ~30 months after enactment, and several at multi‑year offsets).